Danita Jones

1 week ago | angioedemanews.com | Marisa Wexler |Danita Jones |Andrea Lobo |Margarida Maia

A simple diagnostic score may help distinguish between two types of angioedema — mast cell-mediated angioedema and drug-induced nonallergic angioedema — in people taking angiotensin-converting enzyme (ACE) inhibitors, researchers said. They described the scoring system in the study, “Angiotensin-converting enzyme inhibitor-induced angioedema: Proposal for a diagnostic score,” published in the World Allergy Organization Journal.

3 weeks ago | angioedemanews.com | Margarida Maia |Danita Jones |Marisa Wexler |Andrea Lobo

Keeping symptoms of hereditary angioedema (HAE) under control is the most important factor contributing to a better quality of life, according to a study carried out by scientists reporting from India and noting severe limits on access to first-line medications there. “There is an urgent need for easy availability and affordability of first-line medications in resource-limited settings like ours to have better disease control and [quality of life],” the researchers wrote.

1 month ago | angioedemanews.com | Marisa Wexler |Patricia Inacio |Andrea Lobo |Danita Jones

Short-term preventive treatment before dental procedures may not be necessary for people with hereditary angioedema (HAE) who are already on long-term prophylaxis, according to a new study by researchers in Germany. It’s well-established that dental procedures and surgeries can act as triggers to increase the risk of the swelling attacks that mark HAE. As such, people with the genetic disorder are typically given short-term prophylaxis — preventive treatment dubbed STP — before such procedures.

1 month ago | angioedemanews.com | Andrea Lobo |Marisa Wexler |Danita Jones |Steve Bryson

An oral granule formulation of Orladeyo (berotralstat) was safe and well tolerated, and able to reduce the rates of swelling attacks in children with hereditary angioedema (HAE), according to an interim analysis of an ongoing Phase 3 trial. The open-label Phase 3 APeX-P trial (NCT05453968) is assessing the safety and pharmacological properties of once-daily Orladeyo oral granules in children with HAE, ages 2 to 11.

2 months ago | angioedemanews.com | Lindsey Shapiro |Patricia Inacio |Danita Jones |Margarida Maia

The European Commission has approved Andembry (garadacimab) as a monthly treatment for preventing swelling attacks in people with hereditary angioedema (HAE), ages 12 and older. The decision, which is consistent with a recommendation issued by a European Medicines Agency committee last year, is valid in all countries of the European Union, as well as Iceland, Liechtenstein, and Norway.